Flightpath Licenses the First Antibiotic that Selectively Kills Lyme Disease Spirochetes

BERKELEY, Calif.--(BUSINESS WIRE)--Flightpath Biosciences, Inc, a biotechnology company advancing microbiome-sparing therapeutics and diagnostics for infectious diseases, licensed a developmental antibiotic FP-100 acting selectively against a range of spirochetal pathogens from Northeastern University. Today, research describing FP-100 and its properties was published in Cell. The lead author, Dr. Kim Lewis, is...

Click to view original post